A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Cediranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 30 Aug 2013 Planned end date changed from 1 Mar 2007 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 29 Jul 2008 Status changed from recruiting to in progress, according to ClinicalTrials.gov.